Impact Assessment Summary
|Factors ||Initial Effect ||Expected 1yr Recovery ||Comments |
|Company Sales/Revenue ||Weak ||Weak ||Increasing demand for interoperability among healthcare facilities, epidemiologist, and physicians will partially mask the negative impact of COVID-19 on the HCIT market. Nonetheless, there remains uncertainty regarding future capital investments into HCIT among healthcare facilities. |
|ASPs ||Weak ||Weak ||ASPs will remain largely unchanged and will not be significantly impacted by the pandemic. Pricing of HCIT hardware will increase slightly, driven by the disruption of the hardware supply chain. |
|New Product Launches ||Weak ||Weak ||Early-stage innovation will slow, whereas products in late stages of development should launch as scheduled. |
|Supply Chain ||Weak ||Weak ||As the majority of HCIT solutions are software and cloud based, the supply chain will not be significantly impacted. |
*General guidance: Weak: 0-10% change in values/timelines; Moderate: 10-20% change in values/timelines; Strong: >20% change in values/timelines. DRG Medtech is developing a robust quantitative framework for our market forecasts; impact metrics shown here may change in the future to align with those used in the quantitative framework.